Literature DB >> 19609572

Osteotomy and primary wound closure in bisphosphonate-associated osteonecrosis of the jaw: a prospective clinical study with 12 months follow-up.

Philipp Stockmann1, Eleftherios Vairaktaris, Falk Wehrhan, Martin Seiss, Stephan Schwarz, Bernd Spriewald, Friedrich-Wilhelm Neukam, Emeka Nkenke.   

Abstract

GOALS OF WORK: This is a prospective clinical study aimed at assessing the success rate of osteotomy and primary wound closure in patients with bisphosphonate-associated osteonecrosis of the jaw (BONJ).
MATERIALS AND METHODS: Fifty patients who had received bisphosphonates intravenously and subsequently suffered from BONJ were included in the study. All patients underwent osteotomy of the affected jaw bone region and primary wound closure under general anaesthesia. They were followed up bimonthly for a period of 12 months.
RESULTS: Macroscopically altered bone could be completely removed in all cases. In two patients with plasmocytoma, major bleeding occurred postoperatively that required monitoring in an intensive care unit. In two cases, recurrence of BONJ was diagnosed during the first 2 months. In three patients, recurrence appeared between the fourth and the sixth month. In these cases, an additional osteotomy had to be performed. Six patients died during the follow-up period. In the remaining 39 patients, no signs of recurrence could be detected during the follow-up of 12 months. The success rate of the surviving patients was 89% after 1 year.
CONCLUSION: Due to the high success rate of osteotomy and primary wound closure, it should be checked for every patient suffering from BONJ if osteotomy is a viable treatment option.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19609572     DOI: 10.1007/s00520-009-0688-1

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  39 in total

1.  Intravenous bisphosphonates and osteonecrosis.

Authors:  Martin S Greenberg
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2004-09

2.  Hyperbaric oxygen in addition to antibiotic therapy is effective for bisphosphonate-induced osteonecrosis of the jaw in a patient with multiple myeloma.

Authors:  Kazuho Shimura; Chihiro Shimazaki; Kyoko Taniguchi; Sonoko Akamatsu; Masashi Okamoto; Ryo Uchida; Ken-ichi Nomura; Tohru Inaba; Shigeo Horiike; Narisato Kanamura; Masafumi Taniwaki
Journal:  Int J Hematol       Date:  2006-11       Impact factor: 2.490

3.  Morbidity of harvesting of chin grafts: a prospective study.

Authors:  E Nkenke; S Schultze-Mosgau; M Radespiel-Tröger; F Kloss; F W Neukam
Journal:  Clin Oral Implants Res       Date:  2001-10       Impact factor: 5.977

4.  Myeloma and monoclonal gammopathy of uncertain significance associated with acquired von Willebrand's syndrome. Seven new cases with a literature review.

Authors:  V Lamboley; Laurent Zabraniecki; P Sie; J Pourrat; Bernard Fournié
Journal:  Joint Bone Spine       Date:  2002-01       Impact factor: 4.929

5.  Bisphosphonate treatment inhibits the growth of prostate cancer cells.

Authors:  M V Lee; E M Fong; F R Singer; R S Guenette
Journal:  Cancer Res       Date:  2001-03-15       Impact factor: 12.701

6.  Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group.

Authors:  Lee S Rosen; David Gordon; Simon Tchekmedyian; Ronald Yanagihara; Vera Hirsh; M Krzakowski; M Pawlicki; Paul de Souza; Ming Zheng; Gladys Urbanowitz; Dirk Reitsma; John J Seaman
Journal:  J Clin Oncol       Date:  2003-08-15       Impact factor: 44.544

7.  Biphosphonate-associated osteonecrosis can be controlled by nonsurgical management.

Authors:  Lucio Montebugnoli; Laura Felicetti; Davide Bartolomeo Gissi; Angelo Pizzigallo; Gian Andrea Pelliccioni; Claudio Marchetti
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2007-05-07

8.  Ozone therapy in the treatment of avascular bisphosphonate-related jaw osteonecrosis.

Authors:  Allesandro Agrillo; Claudio Ungari; Fabio Filiaci; Paolo Priore; Giorgio Iannetti
Journal:  J Craniofac Surg       Date:  2007-09       Impact factor: 1.046

9.  Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research.

Authors:  Sundeep Khosla; David Burr; Jane Cauley; David W Dempster; Peter R Ebeling; Dieter Felsenberg; Robert F Gagel; Vincente Gilsanz; Theresa Guise; Sreenivas Koka; Laurie K McCauley; Joan McGowan; Marc D McKee; Suresh Mohla; David G Pendrys; Lawrence G Raisz; Salvatore L Ruggiero; David M Shafer; Lillian Shum; Stuart L Silverman; Catherine H Van Poznak; Nelson Watts; Sook-Bin Woo; Elizabeth Shane
Journal:  J Bone Miner Res       Date:  2007-10       Impact factor: 6.741

10.  Incomplete fibrin formation and highly elevated Factor XIII activity in multiple myeloma.

Authors:  H G Klingemann; R Egbring; K Havemann
Journal:  Scand J Haematol       Date:  1981-10
View more
  40 in total

1.  Outcome of treatment and parameters influencing recurrence in patients with bisphosphonate-related osteonecrosis of the jaws.

Authors:  Thomas Mücke; Janett Koschinski; Herbert Deppe; Stefan Wagenpfeil; Christoph Pautke; David A Mitchell; Klaus-Dietrich Wolff; Frank Hölzle
Journal:  J Cancer Res Clin Oncol       Date:  2010-10-07       Impact factor: 4.553

Review 2.  Osteonecrosis of the jaw and bisphosphonates in cancer: a narrative review.

Authors:  Cesar A Migliorati; Joel B Epstein; Elliot Abt; James R Berenson
Journal:  Nat Rev Endocrinol       Date:  2010-11-16       Impact factor: 43.330

3.  The outcome after surgical therapy of bisphosphonate-associated osteonecrosis of the jaw--results of a clinical case series with an average follow-up of 20 months.

Authors:  Philipp Stockmann; Moritz Burger; Cornelius von Wilmowsky; Tobias Ebker; Rainer Lutz; Anne Bauersachs; Emeka Nkenke; Friedrich Wilhelm Neukam; Falk Wehrhan
Journal:  Clin Oral Investig       Date:  2013-08-29       Impact factor: 3.573

4.  Bisphosphonate-associated osteonecrosis of the mandible: reliable soft tissue reconstruction using a local myofascial flap.

Authors:  Juliana Lemound; Andrè Eckardt; Horst Kokemüller; Constantin von See; Pit Jacob Voss; Frank Tavassol; Martin Rücker; Majeed Rana; Nils-Claudius Gellrich
Journal:  Clin Oral Investig       Date:  2011-08-05       Impact factor: 3.573

5.  Treatment of stage II medication-related osteonecrosis of the jaw with necrosectomy and autologous bone marrow mesenchymal stem cells.

Authors:  Pit Jacob Voss; Akihiko Matsumoto; Esteban Alvarado; Rainer Schmelzeisen; Fabian Duttenhöfer; Philipp Poxleitner
Journal:  Odontology       Date:  2017-02-20       Impact factor: 2.634

Review 6.  A literature review of perioperative antibiotic administration in surgery for medication-related osteonecrosis of the jaw.

Authors:  Masaya Akashi; Junya Kusumoto; Daisuke Takeda; Takashi Shigeta; Takumi Hasegawa; Takahide Komori
Journal:  Oral Maxillofac Surg       Date:  2018-10-16

7.  Osteonecrosis of the jaw from bone anti-resorptives: impact of skeletal site-dependent mesenchymal stem cells.

Authors:  So Akintoye
Journal:  Oral Dis       Date:  2013-10-07       Impact factor: 3.511

8.  Osteo-radio-necrosis (ORN) and bisphosphonate-related osteonecrosis of the jaws (BRONJ): the histopathological differences under the clinical similarities.

Authors:  Konstantinos T Mitsimponas; Patrick Moebius; Kerstin Amann; Philipp Stockmann; Karl-Andreas Schlegel; Friedrich-Wilhelm Neukam; Falk Wehrhan
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15

Review 9.  Surgical management of bisphosphonate-related osteonecrosis of the jaws: literature review.

Authors:  Larissa Fernandes Silva; Cláudia Curra; Marcelo Salles Munerato; Carlos Cesar Deantoni; Mariza Akemi Matsumoto; Camila Lopes Cardoso; Marcos Martins Curi
Journal:  Oral Maxillofac Surg       Date:  2015-12-11

10.  Expression of Msx-1 is suppressed in bisphosphonate associated osteonecrosis related jaw tissue-etiopathology considerations respecting jaw developmental biology-related unique features.

Authors:  Falk Wehrhan; Peter Hyckel; Jutta Ries; Phillip Stockmann; Emeka Nkenke; Karl A Schlegel; Friedrich W Neukam; Kerstin Amann
Journal:  J Transl Med       Date:  2010-10-13       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.